WO2000003745A3 - Polysaccharide vaccine for staphylococcal infections - Google Patents

Polysaccharide vaccine for staphylococcal infections Download PDF

Info

Publication number
WO2000003745A3
WO2000003745A3 PCT/US1999/016129 US9916129W WO0003745A3 WO 2000003745 A3 WO2000003745 A3 WO 2000003745A3 US 9916129 W US9916129 W US 9916129W WO 0003745 A3 WO0003745 A3 WO 0003745A3
Authority
WO
WIPO (PCT)
Prior art keywords
infections
adhesin
relates
polysaccharide vaccine
staphylococcal infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/016129
Other languages
French (fr)
Other versions
WO2000003745A2 (en
Inventor
Gerald B Pier
David Mckenney
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA2333931A priority Critical patent/CA2333931C/en
Priority to JP2000559879A priority patent/JP5490341B2/en
Priority to AU50001/99A priority patent/AU771563C/en
Priority to EP99934091A priority patent/EP1096952B1/en
Priority to DK99934091T priority patent/DK1096952T3/en
Priority to DE69938784T priority patent/DE69938784D1/en
Publication of WO2000003745A2 publication Critical patent/WO2000003745A2/en
Publication of WO2000003745A3 publication Critical patent/WO2000003745A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of infections.
PCT/US1999/016129 1998-07-15 1999-07-15 Polysaccharide vaccine for staphylococcal infections Ceased WO2000003745A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2333931A CA2333931C (en) 1998-07-15 1999-07-15 Polysaccharide vaccine for staphylococcal infections
JP2000559879A JP5490341B2 (en) 1998-07-15 1999-07-15 Polysaccharide vaccine for Staphylococcus infection
AU50001/99A AU771563C (en) 1998-07-15 1999-07-15 Polysaccharide vaccine for staphylococcal infections
EP99934091A EP1096952B1 (en) 1998-07-15 1999-07-15 Polysaccharide vaccine for staphylococcal infections
DK99934091T DK1096952T3 (en) 1998-07-15 1999-07-15 Polysaccharide vaccine against staphylococcal infections
DE69938784T DE69938784D1 (en) 1998-07-15 1999-07-15 POLYSACCHARIDE VACCINE AGAINST STAPHYLOKOKEN INFECTIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9311798P 1998-07-15 1998-07-15
US60/093,117 1998-07-15

Publications (2)

Publication Number Publication Date
WO2000003745A2 WO2000003745A2 (en) 2000-01-27
WO2000003745A3 true WO2000003745A3 (en) 2000-04-20

Family

ID=22237266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016129 Ceased WO2000003745A2 (en) 1998-07-15 1999-07-15 Polysaccharide vaccine for staphylococcal infections

Country Status (11)

Country Link
EP (2) EP1967203A1 (en)
JP (1) JP5490341B2 (en)
AT (1) ATE395931T1 (en)
AU (1) AU771563C (en)
CA (1) CA2333931C (en)
CY (1) CY1108542T1 (en)
DE (1) DE69938784D1 (en)
DK (1) DK1096952T3 (en)
ES (1) ES2308844T3 (en)
PT (1) PT1096952E (en)
WO (1) WO2000003745A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CA2434546C (en) * 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
WO2003053462A2 (en) * 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US20060210555A1 (en) 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PL229487B1 (en) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Polysaccharide vaccine for staphylococcal infections
AU2014277807B2 (en) * 2004-04-21 2017-05-25 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
ES2415358T3 (en) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine binding peptides (PNAG / DPNAG) and methods for using them
AU2012205180B2 (en) * 2004-04-21 2014-10-09 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine(PNAG/DPNAG)-binding peptides and methods of use thereof
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
RU2419628C2 (en) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Immunogenic composition for use in vaccination against staphylococci
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN102159540B (en) 2008-07-21 2015-08-12 布赖汉姆妇女医院 Methods and compositions related to synthetic beta-1,6 glucosamine oligosaccharides
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902616A (en) * 1987-08-03 1990-02-20 Institut Pasteur Process for the preparation of capsular polysaccharides of staphylococci, the polysaccharides obtained, uses of these polysaccharides and strains for carrying out of the process
WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (en) * 1988-12-16 1990-06-22 Commissariat Energie Atomique beta -(1->6) Bonded oligosaccharides, in particular 2-acetamido-2-deoxy-glucoses or -galactoses and their preparation.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
FR2046920B1 (en) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902616A (en) * 1987-08-03 1990-02-20 Institut Pasteur Process for the preparation of capsular polysaccharides of staphylococci, the polysaccharides obtained, uses of these polysaccharides and strains for carrying out of the process
WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (en) * 1988-12-16 1990-06-22 Commissariat Energie Atomique beta -(1->6) Bonded oligosaccharides, in particular 2-acetamido-2-deoxy-glucoses or -galactoses and their preparation.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FATTOM A ET AL: "Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 13, no. 14, 1 October 1995 (1995-10-01), pages 1288 - 1293, XP004057429, ISSN: 0264-410X *
KOJIMA Y ET AL: "Antibody to the capsular polysaccharide/adhesin protects rabbits against catheter-related bacteremia due to coagulase-negative staphylococci", J INFECT DIS, vol. 162, no. 2, August 1990 (1990-08-01), pages 435 - 41, XP000867597 *
LEE J C ET AL: "Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus.", INFECTION AND IMMUNITY, (1987 SEP) 55 (9) 2191-7., XP002129164 *
MACK D ET AL: "The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: Purification and structural analysis", JOURNAL OF BACTERIOLOGY, vol. 178, no. 1, January 1996 (1996-01-01), pages 175 - 183, XP000867576 *
MCKENNEY D ET AL: "Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.", SCIENCE, (1999 MAY 28) 284 (5419) 1523-7., XP002129165 *
MCKENNEY D ET AL: "The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide /adhesin.", INFECTION AND IMMUNITY, (1998 OCT) 66 (10) 4711-20., XP002129166 *
WESSELS M R ET AL: "Isolation and characterization of type IV group B Streptococcus capsular polysaccharide.", INFECTION AND IMMUNITY, (1989 APR) 57 (4) 1089-94., XP002129163 *

Also Published As

Publication number Publication date
ES2308844T3 (en) 2008-12-01
DE69938784D1 (en) 2008-07-03
AU771563C (en) 2004-10-28
JP5490341B2 (en) 2014-05-14
AU771563B2 (en) 2004-03-25
EP1096952B1 (en) 2008-05-21
CY1108542T1 (en) 2014-04-09
CA2333931C (en) 2013-09-03
AU5000199A (en) 2000-02-07
ATE395931T1 (en) 2008-06-15
EP1967203A1 (en) 2008-09-10
EP1096952A2 (en) 2001-05-09
CA2333931A1 (en) 2000-01-27
PT1096952E (en) 2008-08-27
JP2002520374A (en) 2002-07-09
WO2000003745A2 (en) 2000-01-27
DK1096952T3 (en) 2008-08-25

Similar Documents

Publication Publication Date Title
CY1108542T1 (en) POLYSYCHARITE VACCINE FOR STAFFIC INFECTIONS
WO2004043405A3 (en) Polysaccharide vaccine for staphylococcal infections
EP1075837A3 (en) Process for the preparation of aqueous formulations for ophthalmic use
AU5242000A (en) Nematicidal trifluorobutenes
AU3973697A (en) Isoxazoline derivatives useful as antimicrobials
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2006002840A3 (en) Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
WO2005000878A3 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
WO2001074788A8 (en) 2-hydroxy-mutilin carbamate derivatives for antibacterial use
WO2002042310A3 (en) Oxabicyclo[2.2.1]heptane derivatives as pesticidal agents
EP0707000A4 (en) Aldoxime derivative and agrohorticultural bactericide
WO2003046007A3 (en) Treatment of micro-organism infection
WO2001098327A3 (en) Glycopeptide carboxy-saccharide derivatives
WO2004016632A8 (en) Lincomycin derivatives possessing antibacterial activity
AU4621500A (en) Novel aluminosiloxane compound and process for preparing the same
WO2004034961A3 (en) Antimicrobial agents and uses thereof
MXPA02012400A (en) Hetaryl-substituted heterocycles.
WO2001062765A3 (en) Small molecule modulators of g protein-coupled receptor six
WO2005007665A3 (en) Lincomycin derivatives possessing antibacterial activity
WO2004004646A3 (en) O-derivatized nocathiacin derivatives
WO2006132947A3 (en) 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof
NL194530B (en) Branch holder, as well as blank for forming this.
EP2116552A3 (en) Peptides, derivatives thereof, process for producing the same, strain producing the same, and antiviral agent comprising the same as active ingredient
AU1031497A (en) Dithiazoldioxides and the use thereof as microbicides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 50001/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 559879

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2333931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999934091

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999934091

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 50001/99

Country of ref document: AU